Opendata, web and dolomites

3TR SIGNED

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3TR project word cloud

Explore the words cloud of the 3TR project. It provides you a very rough idea of what is the project "3TR" about.

response    centralized    microbiome    mechanisms    stratification    de    analysed    academic    first    interpreted    revolutionize    sustain    taxonomies    harmonization    perform    entities    genomic    carrousel    genetics    pharmaceutical    orphan    input    bioinformatics    specimens    conventional    issue    data    medicine    experts    stools    companies    biomarkers    medication    characterisation    fundamental    novo    groups    made    sponsored    treatment    academy    base    industry    cross    diseased    model    tissues    molecular    shared    smes    care    solutions    team    basic    drug    elucidate    patients    disease    samples    platform    3tr    prior    observational    prospective    designed    diseases    clinical    teamed    statistical    patient    validation    single    implications    blood    sciences    cohort    inform    regulatory    trial    therapies    identification    collection    whom    predictive    benefit    line    standard    fluids    transdisciplinary    progression    competitiveness    phases    output    undertaken   

Project "3TR" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD 

Organization address
address: AVENIDA AMERICO VESPUCIO 15 EDIF S2
city: SEVILLA
postcode: 41092
website: www.juntadeandalucia.es/fundacionprogresoysalud

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 80˙803˙177 €
 EC max contribution 40˙273˙191 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-14-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2026-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD ES (SEVILLA) coordinator 9˙876˙529.00
2    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 2˙700˙000.00
3    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) participant 2˙320˙291.00
4    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 1˙917˙499.00
5    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 1˙665˙250.00
6    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 1˙573˙843.00
7    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) participant 1˙429˙125.00
8    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 1˙170˙877.00
9    OREBRO UNIVERSITY SE (OREBRO) participant 893˙122.00
10    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 890˙500.00
11    STICHTING VUMC NL (AMSTERDAM) participant 836˙688.00
12    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY FR (NANCY CEDEX) participant 825˙030.00
13    FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO IT (MILANO) participant 815˙450.00
14    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 717˙221.00
15    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 682˙941.00
16    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 584˙499.00
17    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 565˙627.00
18    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 560˙011.00
19    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 541˙266.00
20    UNIVERSITY OF LEICESTER UK (LEICESTER) participant 523˙897.00
21    UNIVERSITAT BASEL CH (BASEL) participant 489˙568.00
22    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 387˙450.00
23    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 361˙390.00
24    VIB BE (ZWIJNAARDE - GENT) participant 361˙018.00
25    CLINIQUES UNIVERSITAIRES SAINT-LUC BE (BRUXELLES) participant 354˙942.00
26    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 343˙955.00
27    UNIVERSITE DE BRETAGNE OCCIDENTALE FR (BREST) participant 328˙000.00
28    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO IT (VERCELLI) participant 294˙944.00
29    UNIVERSITA DEGLI STUDI DI CAGLIARI IT (CAGLIARI) participant 294˙924.00
30    UNIVERSITA DI PISA IT (PISA) participant 292˙500.00
31    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) participant 290˙996.00
32    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 287˙500.00
33    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 285˙965.00
34    AZIENDA OSPEDALE UNIVERSITA PADOVA IT (PADOVA) participant 277˙003.00
35    UNIVERSITEIT HASSELT BE (HASSELT) participant 247˙825.00
36    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 241˙798.00
37    ATRYS HEALTH, SA ES (MADRID) participant 237˙562.00
38    UNIVERSITA DEGLI STUDI DI GENOVA IT (GENOVA) participant 236˙249.00
39    Deutsches Rheuma-Forschungszentrum Berlin DE (Berlin) participant 229˙595.00
40    UNIVERSITETET I BERGEN NO (BERGEN) participant 209˙617.00
41    REGION HOVEDSTADEN DK (HILLEROD) participant 201˙780.00
42    PHILIPPS UNIVERSITAET MARBURG DE (MARBURG) participant 201˙565.00
43    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 201˙512.00
44    SIP SERVICE S.R.L. IT (MILANO) participant 201˙500.00
45    UNIVERSITY OF SOUTHAMPTON UK (SOUTHAMPTON) participant 201˙498.00
46    UNIVERSITY OF GLASGOW UK (GLASGOW) participant 201˙000.00
47    SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE FR (PARIS 6) participant 196˙425.00
48    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 192˙500.00
49    THE QUEEN'S UNIVERSITY OF BELFAST UK (BELFAST) participant 161˙201.00
50    AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER IT (FIRENZE) participant 146˙350.00
51    UNIVERSITA DEGLI STUDI DI CATANIA IT (CATANIA) participant 145˙302.00
52    UNIVERSITAIR ZIEKENHUIS GENT BE (GENT) participant 141˙508.00
53    OWLSTONE MEDICAL LIMITED UK (CAMBRIDGE) participant 139˙500.00
54    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 125˙000.00
55    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 120˙875.00
56    EUROPEAN LUNG FOUNDATION UK (SHEFFIELD) participant 110˙675.00
57    GENOS DOO ZA VJESTACENJE I ANALIZU HR (OSIJEK) participant 106˙501.00
58    ALACRIS THERANOSTICS GMBH DE (BERLIN) participant 106˙250.00
59    UNIVERSYTET MEDYCZNY W LODZI. PL (LODZ) participant 80˙600.00
60    LUPUS EUROPE UK (ROMFORD ESSEX) participant 78˙750.00
61    EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING BE (Brussels) participant 70˙416.00
62    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
63    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
64    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
65    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
66    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
67    PFIZER LIMITED UK (SANDWICH) participant 0.00
68    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
69    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00

Map

 Project objective

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3TR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3TR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More